67,184 Shares in Immunome, Inc. (NASDAQ:IMNM) Purchased by Rhumbline Advisers

Rhumbline Advisers purchased a new position in shares of Immunome, Inc. (NASDAQ:IMNM) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 67,184 shares of the company’s stock, valued at approximately $813,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Clear Creek Financial Management LLC boosted its holdings in shares of Immunome by 18.2% during the second quarter. Clear Creek Financial Management LLC now owns 26,188 shares of the company’s stock worth $317,000 after acquiring an additional 4,035 shares during the period. EntryPoint Capital LLC boosted its holdings in shares of Immunome by 21,864.0% during the first quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock worth $136,000 after acquiring an additional 5,466 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Immunome during the second quarter worth approximately $97,000. Jump Financial LLC bought a new stake in shares of Immunome during the fourth quarter worth approximately $172,000. Finally, Sequoia Financial Advisors LLC bought a new stake in shares of Immunome during the second quarter worth approximately $206,000. Institutional investors own 44.58% of the company’s stock.

Insider Activity

In other news, CFO Max Rosett sold 14,380 shares of Immunome stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $16.01, for a total value of $230,223.80. Following the completion of the sale, the chief financial officer now directly owns 47,476 shares in the company, valued at $760,090.76. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, Director Jean Jacques Bienaime acquired 7,000 shares of the stock in a transaction on Friday, August 16th. The stock was acquired at an average cost of $13.94 per share, for a total transaction of $97,580.00. Following the completion of the transaction, the director now directly owns 16,615 shares in the company, valued at $231,613.10. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Max Rosett sold 14,380 shares of the business’s stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $16.01, for a total transaction of $230,223.80. Following the transaction, the chief financial officer now owns 47,476 shares of the company’s stock, valued at $760,090.76. The disclosure for this sale can be found here. 8.60% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Wedbush restated an “outperform” rating and set a $33.00 price objective on shares of Immunome in a report on Tuesday, August 13th. Piper Sandler reduced their price objective on Immunome from $27.00 to $23.00 and set an “overweight” rating for the company in a report on Tuesday, August 13th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Immunome has an average rating of “Buy” and an average target price of $29.00.

Immunome Trading Down 6.6 %

NASDAQ IMNM opened at $14.00 on Tuesday. Immunome, Inc. has a 1-year low of $6.80 and a 1-year high of $30.96. The company has a 50 day moving average of $14.54 and a 200-day moving average of $15.94. The company has a market cap of $839.57 million, a price-to-earnings ratio of -1.85 and a beta of 1.77.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11). Immunome had a negative net margin of 2,435.02% and a negative return on equity of 38.19%. The business had revenue of $2.36 million during the quarter, compared to analyst estimates of $2.62 million. On average, equities research analysts forecast that Immunome, Inc. will post -1.92 earnings per share for the current year.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.